



Enzyme Aids Intranasal Drug Delivery

[View U.S. Patent No. 9,320,800 in PDF format.](#)

WARF: P120322US02

Inventors: Robert Thorne, Jeffrey Lochhead

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing nasal spray containing matrix metalloproteinase-9, which helps drugs get absorbed into the brain and blood.

Overview

Currently, delivering drugs directly into the brain requires invasive surgery. This is because a tight cellular layer called the blood-brain barrier (BBB) not only prevents harmful substances from entering the brain, but also blocks many therapeutic agents.

Major research is now focused on bypassing the BBB and delivering drugs intranasally. While many factors influence how drugs are absorbed via the nose, it is known that certain substances can make the nasal lining, or epithelium, more permeable. Such 'absorption/permeability enhancers' include bile salts and other chemicals. However, none of these are used in conjunction with nasal peptide or protein drugs (e.g., calcitonin, desmopressin and oxytocin) because they can be toxic and cause irreversible damage to epithelial cells.

The Invention

UW-Madison researchers have developed a method to enhance intranasal drug absorption using a naturally occurring endopeptidase, called matrix metalloproteinase-9 (MMP-9). This enzyme makes the nasal epithelium more permeable to drugs by degrading type IV collagen. Nasal spray or drops containing MMP-9 can be administered at the same time or prior to a drug to improve its absorption.

Applications

- Drug delivery
- Use with biopharmaceuticals such as peptides, proteins, oligonucleotides, vectors for gene therapy and stem cells

Key Benefits

- Higher concentrations of drugs can be delivered into the brain and blood.
- Bypasses the blood-brain barrier
- MMP-9 is a natural enzyme and may be better tolerated.

Stage of Development

The development of this technology was supported by WARF Accelerator. WARF Accelerator selects WARF's most commercially promising technologies and provides expert assistance and funding to enable achievement of commercially significant milestones.

WARF uses cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. [See our privacy policy.](#)

Additional Information

OK



WARF
Wisconsin Alumni Research Foundation

| info@warf.org | 608.960.9850

Related Intellectual Property

- [View Continuation Patent in PDF format.](#)

Publications

- Lochhead J.J. and Thorne R.G. 2012. Intranasal Delivery of Biologics to the Central Nervous System. Adv. Drug Deliver. Rev. 64, 614-628.

Tech Fields

- [Therapeutics & Vaccines : CNS](#)

For current licensing status, please contact Andy DeTienne at adetienne@warf.org or 608-960-9857

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. [See our privacy policy.](#)

OK



WARF
Wisconsin Alumni Research Foundation

| info@warf.org | 608.960.9850